According to a recent LinkedIn post from AAVantgarde Bio, CEO Natalia Misciattelli recently appeared on The BioHub – by Avetix podcast to discuss the company’s origins and scientific foundation. The discussion reportedly focused on research from founder Alberto Auricchio and his team at the Telethon Institute of Genetics and Medicine, who developed dual-hybrid and intein-based platforms for delivering large therapeutic genes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that these gene-delivery platforms may have significant potential in treating inherited retinal diseases, with specific reference to Stargardt’s disease and Usher 1b. For investors, this emphasis on platform applicability to multiple indications could point to a broader addressable market and support a pipeline-style valuation framework if clinical data later prove positive.
The LinkedIn post also indicates that AAVantgarde Bio intends to share more information about its clinical programs and mentions upcoming activities in Denver, where it plans to showcase recent clinical developments. This forward-looking communication may imply that the company is approaching or entering key clinical milestones, which could act as future catalysts for funding discussions, strategic partnerships, or valuation reassessments within the ophthalmology and gene therapy space.